All about Stage 3

The proposed rule for Meaningful Use Stage 3 was issued last Friday and a lot of people have had a lot to say about it.

CIO of Beth Israel Deaconess Medical Center in Boston, John Halamka, MD, and Micky Tripathi, president and CEO of the Massachusetts eHealth Collaborative, penned their thoughts on the good, the bad and the ugly of the rule, which was published on Halamka's blog, Life as a Healthcare CIO.

The authors called the rule a good first draft that identifies several potential certification candidates but doesn't "lock in those standards before they are mature and market-tested." It also makes a practical leap into query-based exchange by requiring receipt of records from other entities and patients are given a high priority.

Under bad, Halamka and Tripathi said alignment of clinical quality measures (CQMs) with other Centers for Medicare & Medicaid Services (CMS) programs is good, but the details on CQMs won't be provided until later this year. However, "we’re asked to weigh in now on quality measurement policy issues (such as whether all products should be required to support all measures) absent important information such as how many measures CMS is considering, whether they are all well suited to EHRs, and if they would be generally applicable to all EHR products."

The authors named several other problems including the concept of decoupling, a lack of prioritization and the proposal of some standards that are not sufficiently market-tested.

Under ugly, Halamka and Tripathi cite a high threshold rate--80 percent--for performance of clinical information reconciliation. On top of all the other requirements facing providers, "the collective burden is making practice impossible.

"The sheer number of requirements may stifle innovation and reduce the global competitiveness for the entire U.S. health IT industry by over-regulating features and functions with complicated requirements that only apply to CMS and U.S. special interests. The certification criteria are often not aligned with what EHR users ask for. In some cases, the criteria are completely designed to accrue benefits to people who aren't feeling the opportunity cost. So if certification is loaded by non-EHR users, EHR users are going to find that even if the MU objectives are fewer in number and more focused, that their EHRs are focused on a lot of things they haven't asked for."

Among the professional associations weighing in on the proposed rule is the College of Health Information Management Executives (CHIME) which said they are “pleased to see flexibility built into the Stage 3 proposed objectives. We are still trying to understand the implications of moving all Medicare providers to a single definition of MU by 2018, but are encouraged by the potential for this policy to simplify and streamline the long-term viability of Meaningful Use. We were encouraged by the signals to shorten the 2015 EHR reporting period from 365 to 90 days and make other program improvements through a follow-on rule. We call on CMS to propose policy changes to the “all-or-nothing” construct, lengthen timing between required Stage upgrades, and consider much-needed revisions to the hardship exception categories. These changes will enable far better participation among providers, which will in turn, keep them on a path towards improved care through health IT.”

Plenty more to come on this topic.

Beth Walsh

Clinical Innovation + Technology editor

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.